论文信息 - Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial. - 字舞流文

Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial.

N. Vogelzang | V. Lesovoy | Thomas E. Hutson | O. Lipatov | Connie Chen | B. Rosbrook | S. Al-Shukri | V. Stus | A. Bair | S. Kim